|
|
ALEMTUZUMAB
Resources
MedlinePlus Drug Information: Alemtuzumab (Systemic): Breast-feeding—It is not known if alemtuzumab passes into the breast milk. http://www.nlm.nih.gov/medlineplus/print/druginfo/uspdi/500303.html Drug Information: Alemtuzumab (Systemic) (Print Version): ...any unusual or allergic reaction to alemtuzumab or other monoclonal antibodies. http://www.fda.gov/cder/biologics/products/alemmil050701.htm Alemtuzumab - Product Approval Information - Licensing Action: Alemtuzumab - Product Approval Information - Licensing Action. http://www.clinicaltrials.gov/ct/gui/show/NCT00079768 Clinical Trial: Alemtuzumab to Treat Sporadic Inclusion Body Myositis: Alemtuzumab is a laboratory-made antibody currently approved to treat certain http://www.clinicaltrials.gov/ct/gui/show/NCT00057967 Clinical Trial: Alemtuzumab in Treating Patients With Relapsed or ...: Official Title: Phase II Study of Alemtuzumab in Patients With Relapsed http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44851 National Cancer Institute - Dictionary of Cancer Terms: ...alemtuzumab. A type of monoclonal antibody used in the treatment of leukemia. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12939718&dopt=Abstract Alemtuzumab therapy in B-cell lymphoproliferative disorders.: Alemtuzumab (Campath-1H, Ilex Pharmaceuticals, San Antonio, ... Responses are http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11527007&dopt=Abstract Alemtuzumab (Millennium/ILEX).: Alemtuzumab has received Fast Track designation [304771] and orphan drug http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=286 Product Label: FDA Oncology Tools Approval Summary for Alemtuzumab for Accel. Approv. http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=Alemtuzumab Product Label: FDA Oncology Tools Product Label Details in Conventional Order for alemtuzumab http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_03-C-0304.html Clinical Study: 03-C-0304, Pilot Trial of Alemtuzumab and Dose ...: Not pregnant or nursing, because of the unknown effects of Alemtuzumab on the http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_04-N-0133.html Clinical Study: 04-N-0133, Effects of aT Cell-Depleting Monoclonal ...: This study will examine the safety and effectiveness of alemtuzumab (Campath® http://cancer.gov/clinicaltrials/COG-ADVL0222 National Cancer Institute - Clinical Trials (PDQ®): Determine the response rate to alemtuzumab alone and in combination with http://www.cms.hhs.gov/mcd/index_local_alpha.asp?from=alphalmrp&letter=A Centers for Medicare & Medicaid Services: ...view details L5395, Alemtuzumab (Campath®). view details L12237, http://www.visn20.med.va.gov/webRx/restrfile.html?restr=AcetylcysteineIV VISN 20 Formulary - Restrictions: Alemtuzumab (Campath)is non-formulary, restricted to National VA criteria, http://www.nci.nih.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page7 Academic resources: http://www.ufscc.ufl.edu/cancernews.aspx?section=cancernews&id=23589 University of Florida Shands Cancer Center: According to a recent article published in the journal Blood, the monoclonal antibody http://www.cancer.dartmouth.edu/clinicaltrials/trials/F0334.shtml Phase II Trial Comparing Combination Treatment with Fludarabine ...: Phase II Trial Comparing Combination Treatment with Fludarabine and Alemtuzumab http://www.oncolink.upenn.edu/conferences/article.cfm?c=3&s=20&ss=132&id=746 OncoLink | The Web's First Cancer Resource: Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity http://irt-web.stanford.edu/clinical_trials/app/clinical_trials/summary.do?trialId=33126&condition_superordinate=19474551 Phase II Trial Comparing Combination Treatment with Fludarabine ...: Quick Links... ... http://www.med.miami.edu/news/view.asp?id=51 News - University of Miami School of Medicine: Campath-1H, also called Alemtuzumab, is an approved form of treatment for patients http://www.osuccc.osu.edu/9175.cfm?press_releases_id=152&details=t OSU Comprehensive Cancer Center: Byrd says alemtuzumab appears to be helpful for many of them. He and http://www.osuccc.osu.edu/9187.cfm?person_id=230 OSUCCC: Blum KA, Byrd JC. Blood 103(9): 3278-3281, 2004. Alemtuzumab is an effective therapy http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/DM02-593 MDACC Study Summary DM02-593: Study Summary Title. A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, http://cancer.duke.edu/programs/BMT/research.asp Duke Comprehensive Cancer Center: We are continuing to refine and attempt to improve on our engraftment and immune http://med.stanford.edu/profiles/frdActionServlet?choiceId=showPublication&pubid=46459&fid=4695 Drug ingredients index Search the web for more on ALEMTUZUMAB : Mongabay Home | Rainforests | Madagascar | Contact ] © 2006 Rhett A. Butler. |
|
Copyright Rhett A. Butler 2006 |
